National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] Draft guidance Technology appraisal guidance 4 November 2025 ...